Bristol Myers Squibb (BMY) Total Liabilities (2009 - 2026)

Bristol Myers Squibb has disclosed Total Liabilities across 18 years of filings, most recently posting $66.4 billion for Q1 2026.

• In Q1 2026, Total Liabilities fell 11.48% year-over-year to $66.4 billion; the TTM figure through Mar 2026 stood at $66.4 billion (down 11.48% YoY), while the FY2025 annual figure was $71.5 billion, down 6.14% from the prior year.
• Total Liabilities slipped to $66.4 billion in Q1 2026, from $71.5 billion in the prior quarter.
• Over the last five years, Total Liabilities for BMY reached as high as $82.5 billion in Q1 2024 and fell as low as $61.5 billion in Q2 2023.
• The 5-year median for Total Liabilities is $71.4 billion (2022), against an average of $70.8 billion.
• Annual changes were most pronounced in 2023 — Total Liabilities dropped 12.6% — and 2024, when it soared 32.19%.
• A 5-year view of Total Liabilities shows it stood at $65.7 billion in 2022, then retreated by 0.04% to $65.7 billion in 2023, then climbed by 16.05% to $76.2 billion in 2024, then fell by 6.14% to $71.5 billion in 2025, then slipped by 7.21% to $66.4 billion in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $66.4 billion, $71.5 billion, and $78.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.